| |
| |
|
| Insider
Information: |
Clackson Timothy P |
| Relationship: |
|
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
737,796 |
|
|
Indirect Shares
|
118,218 |
|
|
| Direct
Value |
$359,460 |
|
|
|
Indirect Value
|
$181,747 |
|
|
| Total
Shares |
856,014 |
|
|
| Total
Value |
$541,208 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ariad Pharmaceuticals Inc |
ARIA |
President, R&D, CSO |
2016-03-22 |
316,212 |
2004-01-05 |
0 |
Premium* |
|
|
F-star Therapeutics, Inc |
FSTX |
Director |
2020-09-30 |
50,486 |
2018-07-02 |
0 |
Premium* |
|
|
Forma Therapeutics Holdings, Inc., |
FMTX |
Director |
2022-10-14 |
0 |
|
0 |
Premium* |
|
|
Theseus Pharmaceuticals, Inc. |
THRX |
President and CEO, Dir... |
2022-11-11 |
351,030 |
|
0 |
Premium* |
|
|
Xilio Therapeutics, Inc. |
XLO |
10% Owner |
2021-10-21 |
20,068 |
2021-10-21 |
70,888 |
Premium* |
|
|
Elevation Oncology, Inc. |
ELEV |
|
2023-09-01 |
0 |
2023-09-01 |
47,330 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
94 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ELEV |
Elevation Oncology, Inc. |
|
– • – |
2023-09-01 |
4 |
GD |
$0.00 |
$0 |
D/D |
15,777 |
0 |
0 |
- |
|
| FMTX |
Forma Therapeutics Holdin... |
Director |
– • – |
2020-06-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
21,572 |
|
- |
|
| THRX |
Theseus Pharmaceuticals, ... |
President and CEOOfficer |
• • – |
2021-10-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
345,930 |
|
- |
|
| XLO |
Xilio Therapeutics, Inc. |
10% Owner |
– – • |
2021-10-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
20,068 |
|
- |
|
| XLO |
Xilio Therapeutics, Inc. |
10% Owner |
– – • |
2021-10-21 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
70,888 |
|
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
Senior VP Chief Scientific Off |
• – – |
2004-01-05 |
4 |
OE |
$0.81 |
$15,827 |
D/D |
12,800 |
69,129 |
|
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
SVP, Chief Scientific Officer |
• – – |
2006-03-10 |
4 |
OE |
$3.69 |
$5,397 |
D/D |
1,300 |
70,429 |
|
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
SrVP, Chief Scientific Officer |
• – – |
2007-07-11 |
4 |
OE |
$4.31 |
$29,103 |
D/D |
6,400 |
76,829 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
• – – |
2011-03-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
38,334 |
153,646 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
• – – |
2011-04-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
52,000 |
193,373 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
• – – |
2011-06-07 |
4 |
OE |
$5.65 |
$339,000 |
D/D |
60,000 |
240,084 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
• – – |
2012-03-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
91,000 |
304,150 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
• – – |
2012-03-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
38,333 |
306,083 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
• – – |
2012-03-26 |
4 |
OE |
$6.39 |
$47,925 |
D/D |
7,500 |
298,250 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
• – – |
2012-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,000 |
277,689 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
• • – |
2012-07-30 |
4 |
OE |
$5.23 |
$121,514 |
D/D |
23,234 |
257,403 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
• • – |
2012-08-15 |
4 |
OE |
$7.56 |
$278,533 |
D/D |
36,843 |
271,012 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
• • – |
2012-08-30 |
4 |
OE |
$2.62 |
$32,503 |
D/D |
10,001 |
244,170 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
• • – |
2012-12-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,500 |
264,082 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
• • – |
2012-12-20 |
4 |
OE |
$5.23 |
$141,210 |
D/D |
27,000 |
282,940 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
• • – |
2013-01-15 |
4 |
OE |
$4.49 |
$292,414 |
D/D |
57,939 |
341,210 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
• • – |
2013-03-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,334 |
344,706 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
• • – |
2013-03-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
38,333 |
376,372 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
• • – |
2013-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,000 |
370,205 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
• • – |
2013-07-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
28,000 |
392,900 |
0 |
- |
|
94 Records found
|
|
Page 3 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
